378 related articles for article (PubMed ID: 20706150)
41. Clinical trial: esomeprazole for moderate-to-severe nighttime heartburn and gastro-oesophageal reflux disease-related sleep disturbances.
Johnson D; Crawley JA; Hwang C; Brown K
Aliment Pharmacol Ther; 2010 Jul; 32(2):182-90. PubMed ID: 20456306
[TBL] [Abstract][Full Text] [Related]
42. [Diagnosis of gastroesophageal reflux disease-related noncardiac chest pain].
Zheng J; Du ZM; Chen MH; Lin JK; Hu PJ
Zhonghua Yi Xue Za Zhi; 2008 May; 88(20):1390-3. PubMed ID: 18953876
[TBL] [Abstract][Full Text] [Related]
43. Esomeprazole in acute and maintenance treatment of reflux oesophagitis: a multicentre prospective study.
Atug O; Giral A; Kalayci C; Dolar E; Isitan F; Oguz D; Ovunc O; Ozgur O; Soykan I; Simsek I; Unal S; Yenice N;
Adv Ther; 2008 Jun; 25(6):552-66. PubMed ID: 18568450
[TBL] [Abstract][Full Text] [Related]
44. Effect of esomeprazole on nighttime heartburn and sleep quality in patients with GERD: a randomized, placebo-controlled trial.
Johnson DA; Orr WC; Crawley JA; Traxler B; McCullough J; Brown KA; Roth T
Am J Gastroenterol; 2005 Sep; 100(9):1914-22. PubMed ID: 16128933
[TBL] [Abstract][Full Text] [Related]
45. The gain in quality-adjusted life months by switching to esomeprazole in those with continued reflux symptoms in primary care: EncomPASS--a cluster-randomized trial.
Moayyedi P; Armstrong D; Hunt RH; Lei Y; Bukoski M; White RJ
Am J Gastroenterol; 2010 Nov; 105(11):2341-6. PubMed ID: 20842110
[TBL] [Abstract][Full Text] [Related]
46. High rate of clinical and endoscopic relapse after healing of erosive peptic esophagitis in children and adolescents.
Yamamoto E; Brito HS; Ogata SK; Machado RS; Kawakami E
J Pediatr Gastroenterol Nutr; 2014 Nov; 59(5):594-9. PubMed ID: 25023576
[TBL] [Abstract][Full Text] [Related]
47. One-week esomeprazole treatment: an effective confirmatory test in patients with suspected gastroesophageal reflux disease.
Johnsson F; Hatlebakk JG; Klintenberg AC; Román J; Toth E; Stubberöd A; Falk A; Edin R
Scand J Gastroenterol; 2003 Apr; 38(4):354-9. PubMed ID: 12739706
[TBL] [Abstract][Full Text] [Related]
48. Phase I, multicenter, randomized, open-label study evaluating the pharmacokinetics and safety profile of repeated once-daily doses of intravenous esomeprazole in children 0 to 17 years of age.
Sandström M; Davidson G; Tolia V; Sullivan JE; Långström G; Lundborg P; Brown K
Clin Ther; 2012 Aug; 34(8):1828-38. PubMed ID: 22832034
[TBL] [Abstract][Full Text] [Related]
49. Intra-oesophageal acid suppression in complicated gastro-oesophageal reflux disease: esomeprazole versus lansoprazole.
Frazzoni M; Manno M; De Micheli E; Savarino V
Dig Liver Dis; 2006 Feb; 38(2):85-90. PubMed ID: 16289976
[TBL] [Abstract][Full Text] [Related]
50. Pharmacokinetics and pharmacodynamics of lansoprazole in children 13 to 24 months old with gastroesophageal reflux disease.
Heyman MB; Zhang W; Huang B; Chiu YL; Amer F; Winter HS
J Pediatr Gastroenterol Nutr; 2007 Jan; 44(1):35-40. PubMed ID: 17204950
[TBL] [Abstract][Full Text] [Related]
51. Effect of acid suppression on gastric myoelectrical activity in GERD.
Chen CL; Yi CH; Kuo TB; Yang CC
Hepatogastroenterology; 2008; 55(85):1353-5. PubMed ID: 18795687
[TBL] [Abstract][Full Text] [Related]
52. Efficacy and safety of once-daily esomeprazole for the treatment of gastroesophageal reflux disease in neonatal patients.
Davidson G; Wenzl TG; Thomson M; Omari T; Barker P; Lundborg P; Illueca M
J Pediatr; 2013 Sep; 163(3):692-8.e1-2. PubMed ID: 23800403
[TBL] [Abstract][Full Text] [Related]
53. Clinical results from a randomized, double-blind, dose-ranging study of pantoprazole in children aged 1 through 5 years with symptomatic histologic or erosive esophagitis.
Baker R; Tsou VM; Tung J; Baker SS; Li H; Wang W; Rath N; Maguire MK; Comer GM
Clin Pediatr (Phila); 2010 Sep; 49(9):852-65. PubMed ID: 20522615
[TBL] [Abstract][Full Text] [Related]
54. Symptom resolution does not predict healing of erosive oesophagitis in Chinese.
Cheung TK; Wong WM; Wong NY; Chan CK; Fung J; Yuen MF; Chan AO; Tong TS; Wong BC
Digestion; 2007; 75(2-3):128-34. PubMed ID: 17671381
[TBL] [Abstract][Full Text] [Related]
55. A multicenter, randomized, double-blind, 8-week comparative trial of standard doses of esomeprazole (40 mg) and omeprazole (20 mg) for the treatment of erosive esophagitis.
Schmitt C; Lightdale CJ; Hwang C; Hamelin B
Dig Dis Sci; 2006 May; 51(5):844-50. PubMed ID: 16642422
[TBL] [Abstract][Full Text] [Related]
56. Randomized controlled trial comparing aerosolized swallowed fluticasone to esomeprazole for esophageal eosinophilia.
Moawad FJ; Veerappan GR; Dias JA; Baker TP; Maydonovitch CL; Wong RK
Am J Gastroenterol; 2013 Mar; 108(3):366-72. PubMed ID: 23399553
[TBL] [Abstract][Full Text] [Related]
57. Improvements with esomeprazole in patients with upper gastrointestinal symptoms taking non-steroidal antiinflammatory drugs, including selective COX-2 inhibitors.
Hawkey C; Talley NJ; Yeomans ND; Jones R; Sung JJ; Långström G; Naesdal J; Scheiman JM;
Am J Gastroenterol; 2005 May; 100(5):1028-36. PubMed ID: 15842575
[TBL] [Abstract][Full Text] [Related]
58. Long-term outcome of microscopic esophagitis in chronic GERD patients treated with esomeprazole or laparoscopic antireflux surgery in the LOTUS trial.
Fiocca R; Mastracci L; Engström C; Attwood S; Ell C; Galmiche JP; Hatlebakk J; Junghard O; Lind T; Lundell L;
Am J Gastroenterol; 2010 May; 105(5):1015-23. PubMed ID: 19904246
[TBL] [Abstract][Full Text] [Related]
59. The effect of acid suppression on sleep and cardiac autonomic regulation in GERD.
Yi CH; Chen CL; Kuo TB; Yang CC
Hepatogastroenterology; 2008; 55(86-87):1649-52. PubMed ID: 19102361
[TBL] [Abstract][Full Text] [Related]
60. Gastroesophageal reflux disease symptoms on antisecretory therapy: acid, non-acid, or no GERD.
Katz PO
Rev Gastroenterol Disord; 2006; 6(3):136-45. PubMed ID: 16957654
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
